Kokalu

Kokalu is a potent sedative used primarily to put animals to sleep, but in the treatment of Izam it becomes a high-risk means of suppressing the convulsions that have proved fatal to other patients. Limuelle administers it before the convulsions begin, seeking to preserve Izam’s breathing and give his body time to combat the disease. The treatment adapts an earlier, exceptional success against rabies into an urgent experiment whose immediate result is a coma, not yet a cure.

Nature and Medical Use

Milalle explains that Kokalu is rarely used on humans: its ordinary purpose is to sedate animals. It acts quickly and does not interfere with respiration, a combination that makes it useful but also unusually dangerous. Its potency carries the possibility that a patient will never wake. The medicine therefore offers no simple assurance of safety; its value lies in controlling a bodily process that is itself threatening life.

The choice is made in Izam’s room after Limuelle examines the boy’s pupils and asks whether convulsions have begun. Hohsalle says they have not. Limuelle proposes injecting Kokalu, and Hohsalle’s startled response registers how unexpected the intervention is. Milalle recognizes its precedent: the treatment recalls the approach used during the Mad Dog of Soola. Hohsalle corrects her, explaining that the sedative used then was bossa, not Kokalu. Milalle answers that Kokalu is more potent than bossa, making the distinction clinically consequential rather than merely verbal.

Precedent and Rationale

Milalle connects Limuelle’s proposal to an earlier case from a few years before, when he saved a young girl who had contracted rabies. She describes it as the only successful case of its kind. Limuelle had used bossa, which, like Kokalu, could render the patient unconscious. By shutting out the brain’s commands to the body, sedation suppressed the convulsions; the account presents unconsciousness not as recovery, but as a way to interrupt the bodily crisis.

The current outbreak has made that logic newly urgent. According to Milalle, patients treated there have died because convulsions arrested their breathing. Limuelle’s plan is to put the brain to sleep and suppress the tremors, allowing the body time to fight the disease agents. The strategy shifts the immediate aim from directly curing the illness to preventing its most lethal symptom from stopping respiration. Its promise rests on the hope that the body can withstand the disease if the convulsions are held back.

Administration and Immediate Result

Limuelle insists that timing is essential: Kokalu must be administered before convulsions begin, because after they start the intervention would be meaningless. Hohsalle is visibly torn, but Limuelle grips his shoulder as he stresses the narrow window for action. Hohsalle then takes a deep breath and nods to Milalle. She leaves to prepare the medicine, with Makokan following to help; Mana also asks permission to accompany them. As the sun descends and the three hurry through the shadowed hall toward the medicine storeroom, Mana asks whether the drug is dangerous. Milalle explains both its use and the possibility that its human patient may never wake.

Once Kokalu is administered, Izam quickly falls into a coma. His breathing is shallow, but it continues. Limuelle waits until that vital sign is confirmed before asking Hohsalle whether he has injected all the new drugs. Hohsalle reports that they have so far repressed symptoms for only about a day and have saved none of the patients. The immediate purpose of Kokalu is thus sharply visible: Izam is unconscious and still breathing, but the medicine has not yet established that he will survive.

Significance in the Treatment

Kokalu’s use brings together an earlier medical precedent and the present outbreak’s repeated failure. Limuelle’s past success with bossa offers a reason to attempt sedation, while the greater potency of Kokalu intensifies the risk. The decision depends on acting before convulsions, and the scene marks the difference between a short-lived suppression of symptoms and a strategy intended to keep breathing intact while the body fights the disease.

The medicine also exposes the uncertain boundary between treatment and danger. Its animal-sedating purpose, rare use in humans, and possibility of a patient never waking all remain part of the choice; the immediate coma does not resolve that uncertainty. Kokalu represents an experimental intervention rather than a proven cure: it buys the possibility of time by suppressing the brain’s commands, while leaving Izam’s eventual recovery open.